Under the deal, the partnership will develop new stabilised non-immunogenic modified RNA therapies (mRNA) for respiratory diseases by using Ethris’ SNIM RNA technology. As per terms of the
Duzallo is a combination of 200mg of lesinurad and 300mg of allopurinol and has been approved by the regulator as a once-daily oral therapy for treating the condition
According to the drug makers, the PARP inhibitor has been approved as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer irrespective of
KAF156, which belongs to the class of the imidazolopiperazines, is a next-generation antimalarial compound that holds capability to treat drug-resistant strains of the malaria parasite. The trial was
The FDA assessed and approved Besponsa under the breakthrough therapy designation and priority review programs. Besponsa is a targeted therapy, which is believed to work by binding to B-cell
Based in Baltimore, Maryland, Insilico Medicine is an American biotechnology startup that uses AI research for drug discovery, aging research and biomarker development. The collaboration to discover novel biological
CA4P is Mateon’s investigational drug, as well as potent and tubulin-binding vascular disrupting agent (VDA). Focus study is assessing CA4P in combination with bevacizumab and physician's choice chemotherapy
Multikine (Leukocyte Interleukin Injection) is being investigated as a potential first-line immunotherapy. Its objective is to harness the immune system of the patient to produce an anti-tumor response.
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, which is designed to uniquely tackle the body’s own immune system to help restore anti-tumor immune response. The combination,
The trial dubbed as OPH1004 had investigated the superiority of Fovista in combination with Eylea (aflibercept) or Avastin (bevacizumab) anti-VEGF therapy over Eylea or Avastin monotherapy. It was
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.